These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9198218)

  • 1. Recombinant von Willebrand factor.
    Schwarz HP; Turecek PL; Pichler L; Mitterer A; Mundt W; Dorner F; Roussi J; Drouet L
    Thromb Haemost; 1997 Jul; 78(1):571-6. PubMed ID: 9198218
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on the management of von Willebrand disease.
    Federici AB
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular basis of von Willebrand disease and its clinical implications.
    Haematologica; 2004 Sep; 89(9):1036. PubMed ID: 15377463
    [No Abstract]   [Full Text] [Related]  

  • 4. [Willebrand disease].
    Lequièvre V
    Rev Infirm; 2006; (122):22-4. PubMed ID: 16881452
    [No Abstract]   [Full Text] [Related]  

  • 5. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand disease: treatment with or without factor VIII?
    Konkle BA
    J Thromb Haemost; 2007 Jun; 5(6):1113-4. PubMed ID: 17590904
    [No Abstract]   [Full Text] [Related]  

  • 8. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M; Mannucci PM
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Variant type von Willebrand disease with defective binding to factor VIII].
    Shima M
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):430-3. PubMed ID: 9833534
    [No Abstract]   [Full Text] [Related]  

  • 12. [Response to DDAVP in von Willebrand disease type II C].
    Batllé Fonrodona J; López Fernández MF; Martín González R; Fernández Villamor A; López Borrasca A; Lasierra Cirujeda J
    Sangre (Barc); 1985; 30(2):181-4. PubMed ID: 3925573
    [No Abstract]   [Full Text] [Related]  

  • 13. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of D-arginine vasopressin in von Willebrand's disease.
    Bala L; Boggio L; Green D
    Curr Hematol Rep; 2005 Jan; 4(1):1-2. PubMed ID: 15610653
    [No Abstract]   [Full Text] [Related]  

  • 15. [Acquired von Willebranol syndrome--its pathophysiology, diagnosis and treatment].
    Mohri H
    Rinsho Ketsueki; 2001 Jul; 42(7):525-36. PubMed ID: 11524842
    [No Abstract]   [Full Text] [Related]  

  • 16. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
    Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
    Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease.
    Trossaërt M; Flaujac C; Jeanpierre E; Drillaud N; Sigaud M; Fouassier M; Ternisien C; de Raucourt E
    Haemophilia; 2020 Mar; 26(2):e44-e48. PubMed ID: 31865618
    [No Abstract]   [Full Text] [Related]  

  • 18. [An inherited hemostatic disorder as the cause of menorrhagia].
    Leebeek FW; Lotgering FK
    Ned Tijdschr Geneeskd; 2002 Mar; 146(12):545-8. PubMed ID: 11938574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No influence of blood group on the responsiveness to desmopressin in type I "platelet normal" von Willebrand's disease.
    Castaman G; Rodeghiero F
    Thromb Haemost; 1995 Mar; 73(3):551-2. PubMed ID: 7667843
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.